Q-omics provides the consensus-scored MLN profile across patient tissues and cancer cell-line models. MLN expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MLN is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, MLN RNA expression shows 9,649 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, THCA, and TGCT as cancer lineages where MLN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MLN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MLN survival associations across molecular data types. MLN RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MLN RNA expression–survival associations across cancer types. High MLN expression shows unfavorable associations in MESO, BRCA, LUSC, LIHC and SARC, but favorable associations in CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for MLN RNA expression.
This table summarizes MLN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MLN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MLN shows lower tumor expression in STAD and higher tumor expression in THCA, HNSC, KIRC, CHOL and LUSC. The THCA box plot shows higher MLN RNA expression in tumor versus normal tissue (log2 FC = +0.112, t-test p = .009).
This table shows molecular features associated with MLN in patient tissues and cancer cell lines. In patient samples, MLN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MLN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
